Medical University of South Carolina, Charleston, SC, USA.
15535Virginia Commonwealth University School of Pharmacy, Richmond, VA, USA.
J Pharm Pract. 2020 Dec;33(6):882-894. doi: 10.1177/0897190019868413. Epub 2019 Aug 11.
Although the mortality from cardiovascular disease has declined, it remains the leading cause of morbidity and mortality in the United States. Dyslipidemia is a modifiable risk factor that plays a significant role in the development of atherosclerotic cardiovascular disease. Treating dyslipidemia by lowering cholesterol, predominately low-density lipoprotein cholesterol, has been shown to reduce cardiovascular events. The first article that provided dyslipidemia bibliographies was published in 2006. Since this time, new therapies have become available and older therapies that were once thought to provide benefit have since been shown to lack positive outcomes and have therefore fallen out of favor for routine use. As the body of evidence continues to expand, clinicians are faced with reevaluating their treatment strategies to ensure optimal outcomes and appropriate use of lipid-lowering therapies. Therefore, this compilation was created to serve as a resource for clinicians. This publication provides an update of key articles in dyslipidemia management including various guidelines and practice-changing randomized controlled trials.
尽管心血管疾病的死亡率有所下降，但它仍是美国发病率和死亡率的主要原因。血脂异常是一个可改变的危险因素，在动脉粥样硬化性心血管疾病的发展中起着重要作用。通过降低胆固醇，主要是低密度脂蛋白胆固醇来治疗血脂异常，已被证明可以减少心血管事件。第一篇提供血脂异常文献的文章发表于 2006 年。从那时起，新的治疗方法已经出现，而曾经被认为有益的旧治疗方法此后被证明缺乏积极的结果，因此已不再受欢迎，不再常规使用。随着证据不断增加，临床医生面临着重新评估他们的治疗策略，以确保最佳的结果和适当使用降脂治疗。因此，编写了这份汇编，作为临床医生的资源。本出版物提供了血脂异常管理方面的关键文章的更新，包括各种指南和改变实践的随机对照试验。
